Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
biphasic insulin aspart
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Subjects with type 2 diabetes
- Subjects with insulin treatment for at least 24 weeks
- Current treatment with premixed biphasic human insulin preparation for at least 12 weeks
- HbA1c lesser than or equal to 11.0%
Exclusion Criteria:
- Recurrent severe hypoglycaemia
- Proliferative retinopathy or maculopathy requiring acute treatment
- Impaired renal function
- Cardiac diseases
- Uncontrolled hypertension
- Subjects with known malignant tumour
- Total daily insulin dose greater than or equal to 100 IU
Sites / Locations
- Novo Nordisk Investigational Site
Outcomes
Primary Outcome Measures
Safety
Secondary Outcome Measures
HbA1c
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00564668
Brief Title
Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes
Official Title
A 24-week, Randomised, Multi-centre, Double-blind, Parallel-group Trial to Investigate the Safety and the Efficacy of NN2000-Mix30 Compared to NN-X14Mix30 NovoRapid®30Mix) in Subjects With Type 2 Diabetes Mellitus on a Twice Daily Regimen
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
June 19, 2004 (Actual)
Primary Completion Date
April 12, 2005 (Actual)
Study Completion Date
April 12, 2005 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in Japan. The aim of this trial was to investigate the safety and efficacy of NN2000-Mix30 produced by NN2000 process compared to that of NN-X14Mix30 produced by current process in Japanese subjects with type 2 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
126 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
biphasic insulin aspart
Primary Outcome Measure Information:
Title
Safety
Time Frame
During 24 weeks of treatment
Secondary Outcome Measure Information:
Title
HbA1c
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects with type 2 diabetes
Subjects with insulin treatment for at least 24 weeks
Current treatment with premixed biphasic human insulin preparation for at least 12 weeks
HbA1c lesser than or equal to 11.0%
Exclusion Criteria:
Recurrent severe hypoglycaemia
Proliferative retinopathy or maculopathy requiring acute treatment
Impaired renal function
Cardiac diseases
Uncontrolled hypertension
Subjects with known malignant tumour
Total daily insulin dose greater than or equal to 100 IU
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
1000005
Country
Japan
12. IPD Sharing Statement
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes
We'll reach out to this number within 24 hrs